PT Kimia Farma Tbk together with RSUPN Dr. Cipto Mangunkusumo (RSCM) and the Faculty of Medicine, University of Indonesia (FKUI) collaborate in research and production of stem cells and their derivatives to produce innovative cell-based products to help treat the Indonesian people.

This stem cell development production facility has obtained a Good Manufacturing Practices (CPOB) certificate from the Food and Drug Supervisory Agency (BPOM) which was handed over directly by the Acting Head of BPOM Rizka Andalucia. This facility is one of three stem cell facilities in Indonesia that has a CPOB certificate and the only facility that is located in a hospital. Previously, the stem cell production facility had obtained an operational permit from the Ministry of Health.

Innovation in the use of stem cells and their derivatives in treating diseases is currently very promising. Several diseases that can be treated using stem cells and their derivatives include osteoarthritis, Herniated Nucleus Pulposus (HNP), pneumonia, stroke, baldness, skin rejuvenation, melasma and others.

Kimia Farma is committed to continuing to innovate in creating future treatments (advanced therapy medicinal products) that are greatly needed by the community. Collaboration between the Company and RSCM and FKUI researchers is expected to support the independence of domestic biological products.